However, the use of dasatinib is still hindered by the capacity of CML cells to acquire drug resistance, which can be prevented by combining Dasatinib with TNF-related apoptosis-inducing ligand (TRAIL), a component of the TNF superfamily. This evidence concerns the gene TNFSF10 and chronic myelogenous leukemia, BCR-ABL1 positive.